News

The approval covers Bosaya in a 60mg/ml prefilled syringe and Vevzuo in a 120mg/1.7ml (70mg/ml) single-dose vial, both for subcutaneous injection. Denosumab therapies are used to increase bone

The application aims to allow the use of this combination therapy for all patients with MIBC, regardless of their cisplatin eligibility. It could potentially broaden the approved use,

The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately €780m ($920.7m) earlier this year. The acquisition aligns with Asahi Kasei’s

The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is

This approval authorises Enflonsia’s marketing across all 27 European Union member states, Iceland, Liechtenstein and Norway. Enflonsia is a long-acting monoclonal antibody intended for prevention, providing protection over

This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities. Interna’s MNM molecules

The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data,

This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim’s DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with